Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia

Beat Müller, Stephan Harbarth, Daiana Stolz, Roland Bingisser, Christian Mueller, Jörg Leuppi, Charly Nusbaumer, Michael Tamm, Mirjam Christ-Crain, Beat Müller, Stephan Harbarth, Daiana Stolz, Roland Bingisser, Christian Mueller, Jörg Leuppi, Charly Nusbaumer, Michael Tamm, Mirjam Christ-Crain

Abstract

Background: Community-acquired pneumonia (CAP) is the most frequent infection-related cause of death. The reference standard to diagnose CAP is a new infiltrate on chest radiograph in the presence of recently acquired respiratory signs and symptoms. This study aims to evaluate the diagnostic and prognostic accuracy of clinical signs and symptoms and laboratory biomarkers for CAP.

Methods: 545 patients with suspected lower respiratory tract infection, admitted to the emergency department of a university hospital were included in a pre-planned post-hoc analysis of two controlled intervention trials. Baseline assessment included history, clinical examination, radiography and measurements of procalcitonin (PCT), highly sensitive C-reactive protein (hsCRP) and leukocyte count.

Results: Of the 545 patients, 373 had CAP, 132 other respiratory tract infections, and 40 other final diagnoses. The AUC of a clinical model including standard clinical signs and symptoms (i.e. fever, cough, sputum production, abnormal chest auscultation and dyspnea) to diagnose CAP was 0.79 [95% CI, 0.75-0.83]. This AUC was significantly improved by including PCT and hsCRP (0.92 [0.89-0.94]; p < 0.001). PCT had a higher diagnostic accuracy (AUC, 0.88 [0.84-0.93]) in differentiating CAP from other diagnoses, as compared to hsCRP (AUC, 0.76 [0.69-0.83]; p < 0.001) and total leukocyte count (AUC, 0.69 [0.62-0.77]; p < 0.001). To predict bacteremia, PCT had a higher AUC (0.85 [0.80-0.91]) as compared to hsCRP (p = 0.01), leukocyte count (p = 0.002) and elevated body temperature (p < 0.001). PCT, in contrast to hsCRP and leukocyte count, increased with increasing severity of CAP, as assessed by the pneumonia severity index (p < 0.001).

Conclusion: PCT, and to a lesser degree hsCRP, improve the accuracy of currently recommended approaches for the diagnosis of CAP, thereby complementing clinical signs and symptoms. PCT is useful in the severity assessment of CAP.

Figures

Figure 1
Figure 1
Receiver operating characteristics curves (ROC) of different parameters for the diagnosis of pneumonia. a diagnostic accuracy to predict CAP without chest radiography: Primary care approach. b diagnostic accuracy to predict radiographically suspected CAP (control group (n = 20) includes other non-infectious diagnoses initially diagnosed as CAP): Emergency department approach. c diagnostic accuracy to predict radiographically suspected CAP (control group (n = 44) includes other non-infectious diagnoses initially diagnosed as CAP (n = 20) plus patients without a clinically relevant bacterial etiology of CAP (n = 24). d diagnostic accuracy to predict bacteremic CAP. Values show areas under the ROC curve with 95% confidence intervals. Chest auscult. denotes abnormal chest auscultation; CRP C-reactive Protein; PCT procalcitonin.
Figure 2
Figure 2
PCT as compared to hsCRP and leukocyte count in different severities of CAP. PCT denotes procalcitonin, CRP highly-sensitive C-reactive protein, PSI pneumonia severity index. Diamonds denote means, squares SEM and whiskers 1.96 SEM of the combined data. The scatterplots represent all values.

References

    1. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, Fine MJ. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 2002;162:1059–1064. doi: 10.1001/archinte.162.9.1059.
    1. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–1754.
    1. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr., Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:1405–1433. doi: 10.1086/380488.
    1. Dalhoff K. Worldwide guidelines for respiratory tract infections: community-acquired pneumonia. Int J Antimicrob Agents. 2001;18 Suppl 1:S39–44. doi: 10.1016/S0924-8579(01)00405-8.
    1. Hoare Z, Lim WS. Pneumonia: update on diagnosis and management. Bmj. 2006;332:1077–1079. doi: 10.1136/bmj.332.7549.1077.
    1. Hopstaken RM, Muris JW, Knottnerus JA, Kester AD, Rinkens PE, Dinant GJ. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Br J Gen Pract. 2003;53:358–364.
    1. Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis. 2004;4:112–124. doi: 10.1016/S1473-3099(04)00931-4.
    1. Goossens H, Little P. Community acquired pneumonia in primary care. Bmj. 2006;332:1045–1046. doi: 10.1136/bmj.332.7549.1045.
    1. O'Donnell WJ, Kradin RL, Evins AE, Wittram C. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-2004. A 52-year-old woman with recurrent episodes of atypical pneumonia. N Engl J Med. 2004;351:2741–2749. doi: 10.1056/NEJMcpc049030.
    1. Genne D, Kaiser L, Kinge TN, Lew D. Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. Clin Microbiol Infect. 2003;9:949–954. doi: 10.1046/j.1469-0691.2003.00679.x.
    1. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278:2080–2084. doi: 10.1001/jama.278.23.2080.
    1. Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet. 2002;359:1648–1654. doi: 10.1016/S0140-6736(02)08597-5.
    1. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–607. doi: 10.1016/S0140-6736(04)15591-8.
    1. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber P, Zimmerli W, Harbarth S, Tamm M, Müller B. Procalcitonin for Initiation and Discontinuation of Antibiotic Therapy in Community-acquired Pneumonia - A randomized Trial [ISRCTN04176397] Am J Respir Crit Care Med . 2006;174:84–93. doi: 10.1164/rccm.200512-1922OC.
    1. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.
    1. Gonzales R, Sande MA. Uncomplicated acute bronchitis. Ann Intern Med. 2000;133:981–991.
    1. National Institutes of Health. National Heart. Lung. and. Blood. Institute Expert panel report 2. Guidelines for the diagnosis and management of asthma. NIH publication. 1997. pp. No 97–4051.
    1. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250. doi: 10.1056/NEJM199701233360402.
    1. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382. doi: 10.1136/thorax.58.5.377.
    1. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden MB. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Jama. 2004;292:1363–1364. doi: 10.1001/jama.292.11.1363.
    1. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004;350:451–458. doi: 10.1056/NEJMoa031544.
    1. Nylen ES, Muller B, Becker KL, Snyder RH. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis. 2003;36:823–824. doi: 10.1086/368088.
    1. Fischer JE, Harbarth S, Agthe AG, Benn A, Ringer SA, Goldmann DA, Fanconi S. Quantifying uncertainty: physicians' estimates of infection in critically ill neonates and children. Clin Infect Dis. 2004;38:1383–1390. doi: 10.1086/420741.
    1. Galetto-Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics. 2003;112:1054–1060. doi: 10.1542/peds.112.5.1054.
    1. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164:396–402.
    1. Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, Ritz R. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000;28:977–983. doi: 10.1097/00003246-200004000-00011.
    1. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.
    1. Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29:1043–1051. doi: 10.1007/s00134-003-1761-8.
    1. Hammerschlag MR, Klein JO, Herschel M, Chen FC, Fermin R. Patterns of use of antibiotics in two newborn nurseries. N Engl J Med. 1977;296:1268–1269.
    1. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. Jama. 1997;278:1440–1445. doi: 10.1001/jama.278.17.1440.
    1. Wipf JE, Lipsky BA, Hirschmann JV, Boyko EJ, Takasugi J, Peugeot RL, Davis CL. Diagnosing pneumonia by physical examination: relevant or relic? Arch Intern Med. 1999;159:1082–1087. doi: 10.1001/archinte.159.10.1082.
    1. Musher DM, Alexandraki I, Graviss EA, Yanbeiy N, Eid A, Inderias LA, Phan HM, Solomon E. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) 2000;79:210–221. doi: 10.1097/00005792-200007000-00002.
    1. Tan MJ, Tan JS, Hamor RH, File TM, Jr., Breiman RF. The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest. 2000;117:398–403. doi: 10.1378/chest.117.2.398.
    1. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 2002;162:1849–1858. doi: 10.1001/archinte.162.16.1849.
    1. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection. 2000;28:68–73. doi: 10.1007/s150100050049.
    1. Moulin F, Raymond J, Lorrot M, Marc E, Coste J, Iniguez JL, Kalifa G, Bohuon C, Gendrel D. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child. 2001;84:332–336. doi: 10.1136/adc.84.4.332.
    1. Carratala J, Fernandez-Sabe N, Ortega L, Castellsague X, Roson B, Dorca J, Fernandez-Aguera A, Verdaguer R, Martinez J, Manresa F, Gudiol F. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med. 2005;142:165–172.
    1. File TM, Jr., Lode H, Kurz H, Kozak R, Xie H, Berkowitz E. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother. 2004;48:3323–3331. doi: 10.1128/AAC.48.9.3323-3331.2004.
    1. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, Bossuyt PM. Empirical evidence of design-related bias in studies of diagnostic tests. Jama. 1999;282:1061–1066. doi: 10.1001/jama.282.11.1061.

Source: PubMed

3
Subscribe